We Offer Worldwide Shipping
Login Wishlist

Gliclazide

$64

  • Brand : BIOFRON

  • Catalogue Number : BN-O1020

  • Specification : 98%(HPLC)

  • CAS number : 21187-98-4

  • Formula : C15H21N3O3S

  • Molecular Weight : 323.41

  • PUBCHEM ID : 3475

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1020

Analysis Method

Specification

98%(HPLC)

Storage

-20℃

Molecular Weight

323.41

Appearance

Powder

Botanical Source

Structure Type

Category

SMILES

CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2

Synonyms

Glyzide/Diaprel/N-(4-Methylbenzenesulfonyl)-N'-(3-azabicyclo[3.3.0]oct-3-yl)urea/Nordialex/Benzenesulfonamide, N-[[(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)amino]carbonyl]-4-methyl-/1-[3-Azabicyclo[3.3.0]oct-3-yl]-3-p-toluenesulfonylurea/Glimicron/1-(3-Azabicyclo[3.3.0]oct-3-yl)-3-p-tolylsulphonylurea/S-1702/1-(Hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea/s852/Gliclazide/N-[[(Hexahydrocyclopenta[c]pyrrol-2(1H)-yl)amino]carbonyl]-4-methylbenzenesulfonamide/se1702/Glinormax/N-(Hexahydrocyclopenta[c]pyrrol-2(1H)-ylcarbamoyl)-4-methylbenzenesulfonamide/1-(3-Azabicyclo[3.3.0]oct-3-yl)-3-(p-tolylsulfonyl)urea/Diamicron/N-[(hexahydrocyclopenta[c]pyrrol-2(1H)-ylamino)carbonyl]-4-methylbenzenesulfonamide/Benzenesulfonamide, N-(((hexahydrocyclopenta(c)pyrrol-2(1H)-yl)amino)carbonyl)-4-methyl-

IUPAC Name

Density

1.4±0.1 g/cm3

Solubility

Flash Point

Boiling Point

Melting Point

163-169 °C(lit.)

InChl

InChI=1S/C37H46O14/c1-18-25(46-19(2)38)16-37(44)32(50-33(43)24-13-11-10-12-14-24)30-35(9,26(47-20(3)39)15-27-36(30,17-45-27)51-23(6)42)31(49-22(5)41)29(48-21(4)40)28(18)34(37,7)8/h10-14,25-27,29-32,44H,15-17H2,1-9H3/t25-,26-,27+,29+,30-,31-,32-,35+,36-,37+/m0/s1

InChl Key

BOVGTQGAOIONJV-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:21187-98-4) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

26924475

Abstract

Sulfonylureas (SUs) remain the most commonly prescribed drug after metformin in the treatment of type 2 diabetes (T2DM), despite the availability of several newer agents. The primary reason of SUs being most popular is their quick glycemic response, time-tested experience and least cost. Although SUs are one amongst the several other second line agents after metformin in all major guidelines, the new Dutch type 2 guidelines specifically advise gliclazide as the preferred second line drug instead of SUs as a class. The World Health Organization (WHO) has also included gliclazide in their Model List of Essential Medicines 2013 motivated by its safety data in elderly patients. Specifically advising gliclazide may have been based on emerging evidence suggesting cardiovascular neutrality of gliclazide over other SUs. This prompted us to do a literature review of gliclazide efficacy and safety data compared to other SUs as well as oral anti-diabetic drugs.

KEYWORDS

Ramadan; Sulfonylureas; cardiovascular mortality; gliclazide; hypoglycemia

Title

Is Gliclazide a Sulfonylurea With Difference? A Review in 2016

Author

Awadhesh Kumar Singh 1, Ritu Singh 1

Publish date

2016 Jun

PMID

28431776

Abstract

Gliclazide is a second-generation oral hypoglycemic drug used for the treatment of noninsulin-dependent diabetes mellitus. It belongs to the sulfonylurea class that stimulates insulin secretion from pancreatic β-cells by inhibiting ATP-dependent potassium channels. Gliclazide also possesses unique antioxidant properties and other beneficial hemobiological effects. This profile represents a comprehensive description of the physical properties, chemical synthesis, spectroscopic characterization (FTIR, 1H NMR, 13C NMR, UV, and single-crystal X-ray), methods of analysis, pharmacological actions, and pharmacokinetic and pharmacodynamic properties of the title drug.

KEYWORDS

Antioxidant activity; Chemical synthesis; Diabetes mellitus; Gliclazide; Hypoglycemic agent; Pharmacokinetics; Single-crystal X-ray diffraction; Spectroscopy; Toxicity.

Title

Gliclazide

Author

Fatmah A M Al-Omary 1

Publish date

2017

PMID

29461148

Title

Der Stellenwert Des Sulfonylharnstoffes Gliclazid Im Vergleich Zu Neueren Oralen Antidiabetika

Author

Alexander Viardot 1

Publish date

2017


Description :

Empty ...